TNF Pharmaceuticals (TNFA) Stock Price, News & Analysis

Company Overview

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Key Stats

• Today's Range: $0.04 to $0.05
• 50-Day Range: $4.83 to $15.44
• 52-Week Range: $0.04 to $1.95
• Volume: 70.40 million shs
• Average Volume: 79.61 million shs
• Market Capitalization: $8.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TNFA Stock Analysis - Frequently Asked Questions

How have TNFA shares performed this year?

TNF Pharmaceuticals' stock was trading at $115.00 at the start of the year. Since then, TNFA stock has decreased by 100.0% and is now trading at $0.0483.

How were TNF Pharmaceuticals' earnings last quarter?

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) issued its quarterly earnings results on Tuesday, August, 19th. The company reported ($18.00) earnings per share (EPS) for the quarter.

When did TNF Pharmaceuticals' stock split?

TNF Pharmaceuticals shares reverse split before market open on Tuesday, September 2nd 2025.The 1-100 reverse split was announced on Thursday, August 28th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of TNF Pharmaceuticals?

Shares of TNFA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TNF Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TNF Pharmaceuticals investors own include Amprius Technologies (AMPX), Archrock (AROC), Axon Enterprise (AXON), PACCAR (PCAR), Bitfarms (BITF), Bitfarms (BFARF) and BigBear.ai (BBAI).

Company Calendar

• Last Earnings: 8/19/2025
• Today: 9/01/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TNFA
• CIK: 1321834
• Web: tnfpharma.com
• Phone: (856) 848-8698
• Fax: 856-848-0269
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.36 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -69.21%
• Return on Assets: -33.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.93
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.87 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 178,620,000
• Free Float: 177,812,000
• Market Cap: $8.63 million
• Optionable: N/A
• Beta: 2.05